127 related articles for article (PubMed ID: 36248324)
1. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report.
Sumi T; Koshino Y; Michimata H; Nagayama D; Watanabe H; Yamada Y; Chiba H
Transl Lung Cancer Res; 2022 Sep; 11(9):1973-1976. PubMed ID: 36248324
[TBL] [Abstract][Full Text] [Related]
2. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
[TBL] [Abstract][Full Text] [Related]
3. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au L; Fendler A; Shepherd STC; Rzeniewicz K; Cerrone M; Byrne F; Carlyle E; Edmonds K; Del Rosario L; Shon J; Haynes WA; Ward B; Shum B; Gordon W; Gerard CL; Xie W; Joharatnam-Hogan N; Young K; Pickering L; Furness AJS; Larkin J; Harvey R; Kassiotis G; Gandhi S; ; Swanton C; Fribbens C; Wilkinson KA; Wilkinson RJ; Lau DK; Banerjee S; Starling N; Chau I; ; Turajlic S
Nat Med; 2021 Aug; 27(8):1362-1366. PubMed ID: 34040262
[TBL] [Abstract][Full Text] [Related]
4. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors.
Ohira J; Kawamoto M; Sugino Y; Kohara N
Medicine (Baltimore); 2020 Apr; 99(15):e19741. PubMed ID: 32282733
[TBL] [Abstract][Full Text] [Related]
5. Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report.
Morita S; Tsuji T; Kishimoto S; Uraki S; Takeshima K; Iwakura H; Furuta H; Nishi M; Inaba H; Matsuoka TA
BMC Endocr Disord; 2022 Jul; 22(1):185. PubMed ID: 35854260
[TBL] [Abstract][Full Text] [Related]
6. Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer.
Tanaka T; Taoka M; Makimoto G; Ninomiya K; Higo H; Fujii M; Ichihara E; Ohashi K; Hotta K; Tabata M; Maeda Y
Intern Med; 2024 May; 63(9):1261-1267. PubMed ID: 37722894
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
Strobel SB; Machiraju D; Kälber KA; Hassel JC
Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
[TBL] [Abstract][Full Text] [Related]
8. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
Walle T; Bajaj S; Kraske JA; Rösner T; Cussigh CS; Kälber KA; Müller LJ; Strobel SB; Burghaus J; Kallenberger SM; Stein-Thöringer CK; Jenzer M; Schubert A; Kahle S; Williams A; Hoyler B; Zielske L; Skatula R; Sawall S; Leber MF; Kunes RZ; Krisam J; Fremd C; Schneeweiss A; Krauss J; Apostolidis L; Berger AK; Haag GM; Zschäbitz S; Halama N; Springfeld C; Kirsten R; Hassel JC; Jäger D; ; Ungerechts G
Nat Cancer; 2022 Sep; 3(9):1039-1051. PubMed ID: 35715501
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
12. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report.
Deng PB; Jiang J; Hu CP; Cao LM; Li M
World J Clin Cases; 2022 Feb; 10(5):1580-1585. PubMed ID: 35211595
[TBL] [Abstract][Full Text] [Related]
13. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
Front Immunol; 2020; 11():1311. PubMed ID: 32676080
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Takai R; Nose T; Ohata S; Nagatani Y; Koyama T; Kitao A; Nishimura M; Imamura Y; Kiyota N; Harada K; Tanaka Y; Mori Y; Minami H
J Infect Chemother; 2022 Apr; 28(4):516-520. PubMed ID: 35090826
[TBL] [Abstract][Full Text] [Related]
18. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
[TBL] [Abstract][Full Text] [Related]
19. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.
Oda H; Ishihara M; Miyahara Y; Nakamura J; Kozuka Y; Iwasa M; Tsunoda A; Yamashita Y; Saito K; Mizuno T; Shiku H; Katayama N
Case Rep Oncol; 2019; 12(1):147-156. PubMed ID: 31043953
[TBL] [Abstract][Full Text] [Related]
20. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
